Join us March 10 for the Hepatitis B Foundation Gala <<Click here>>

Donate

LiverCancerConnect

Welcome to our Liver Cancer Connect Program

Find Clinical Trials Near Me!

Check out resources for Liver Cancer Awareness Month here.

Liver Cancer Drug Survey 1

Click here to take the survey - thank you for your input!

Check out this video with a liver cancer survivor on Closing the Care Gap!

This panel discussion features someone with lived experience of liver cancer and his wife in conversation with researchers and patient advocates. The discussion highlights what is missing in order to improve the lives of people diagnosed with HCC. Check it out today!

Watch our latest webinar! In it, panelists discuss conclusions & insights from a recent project to identify & close disparities in hepatitis B & liver cancer knowledge and screening rates among highly impacted communities around the US. Check it out today!

Liver Cancer Connect is a dedicated program of the Hepatitis B Foundation that was created to provide individuals and families with the information and support they need when facing the challenge of primary liver cancer. Although this is a serious diagnosis, there is good reason to have hope because of the many advances made in the early detection, management and treatment of liver cancer.

In the News

The Cancer Experience Registry is an online survey that allows people facing cancer to share their experiences, identify the issues that impact their life, and help them understand their experiences.

Minimally-invasive surgical options for liver cancer and liver tumors, and other options from the multidisciplinary team from Johns Hopkins (Video)

FDA approves a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer

AstraZeneca’s immunotherapy tremelimumab has secured its first FDA approval and is to be sold under the brand name Imjudo

Antiviral therapy improves survival among elderly patients after hepatectomy for hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC)

New strategies and the partnerships needed to bring early detection of cancer to everyone

Importance of screening for hepatocellular carcinoma in hepatitis B virus: Patient and physician sharing session, a podcast with Ming-Lung Yu, MD, PhD

Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy

JW Therapeutics announces the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma

The American Society for Radiation Oncology (ASTRO) issues clinical guidelines on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

Dr. Gish talks about the importance of liver cancer surveillance and the blood work and imaging involved in regular monitoring - all in less than 2 minutes (Video)

Listen to this episode of B Heppy with Dr. Rothstein about the relationship between liver cancer & hep B (Podcast)

National Comprehensive Cancer Network (NCCN) releases an update to its guideline for hepatobiliary cancers

Immunotherapy for advanced HCC: Experts answer clinician questions

Dr Reddy’s Laboratories announces the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration

Review of insights into the success and failure of systemic therapy for liver cancer

Novartis and BeiGene have announced new data from a phase 3 trial that shows tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma

New Study Shows Options for Older Patients With Liver Cancer

Case 3: Novel Frontline Combination Strategies for Unresectable HCC (Video)

Current and Future Immunotherapy Approaches for HCC: Evidence, Guidance, and Resources (Podcast)

Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)

Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma

Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy

AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer

Assessing the Risk of HCC for Hepatitis B Treatments

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC

Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC

Study Uncovers New Treatment Approaches for Liver Cancer Patients

REACH-B Score for Hepatocellular Carcinoma

Bringing Early Cancer Detection to the Masses

NUS Scientists Discover New Clues to Liver Cancer Progression

How Have Hepatocellular Carcinoma Treatments Improved?

Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma

Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions

Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial

What Gastroenterologists Need to Know About New Guidelines on Systemic HCC Therapy

Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC

About Herbs, Botanicals, and Other Products (from Memorial Sloan Kettering Cancer Center)

Cancer Burden Facing Asian Americans Partly Caused By Racism

New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients

Researchers Identify a New tsRNA in Blood to Improve Liver Cancer Diagnosis

The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.

Pan Tumor Clinical Trial Is Actively Recruiting to Investigate the Effects of Nivolumab When Given Under the Skin With or Without rHuPH20. Learn more!

EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

What Cancer Survivors Should Know About Their Mental Health

Get Connected